Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Yena | - |
dc.contributor.author | Rosenblat, Joshua D. | - |
dc.contributor.author | Lee, JungGoo | - |
dc.contributor.author | Carmona, Nicole E. | - |
dc.contributor.author | Subramaniapillai, Mehala | - |
dc.contributor.author | Shekotikhina, Margarita | - |
dc.contributor.author | Mansur, Rodrigo B. | - |
dc.contributor.author | Brietzke, Elisa | - |
dc.contributor.author | Lee, Jae-Hon | - |
dc.contributor.author | Ho, Roger C. | - |
dc.contributor.author | Yim, Samantha J. | - |
dc.contributor.author | McIntyre, Roger S. | - |
dc.date.accessioned | 2021-09-02T15:51:41Z | - |
dc.date.available | 2021-09-02T15:51:41Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2018-02 | - |
dc.identifier.issn | 0165-0327 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/77840 | - |
dc.description.abstract | Introduction: Work-related disability and productivity loss in Major Depressive Disorder (MDD) are critical determinants of patient quality of life and contribute significantly to the human and economic costs of MDD. Notwithstanding the return to work and pre-morbid levels of functioning as a critical therapeutic objective among individuals with MDD, it is unclear whether antidepressant treatment significantly and reliably improves measures of workplace functioning. Herein, we investigate to what extent antidepressant treatment improves workplace functioning among adults with MDD. Methods: We conducted a systematic review of randomized, double-blind, placebo-controlled or active comparator clinical trials primarily or secondarily investigating the efficacy of antidepressant agents on subjective ratings of workplace functioning and/or measures of work absence. Results: Thirteen placebo-controlled and four active comparator clinical trials reported on the efficacy of agomelatine, bupropion, desvenlafaxine, duloxetine, fluoxetine, levomilnacipran, paroxetine, sertraline, venlafaxine, or vortioxetine on subjective measures of workplace impairment. Overall, antidepressant treatment improved standardized measures of workplace functioning (e.g., Sheehan Disability Scale-work item). One placebo-controlled trial of agomelatine and one clinical trial comparing the efficacy of vortioxetine to that of venlafaxine had mixed results on measures of work absence. Limitations: Included interventional trials evaluated work-related disability as a secondary outcome using subjective rating scales. Conclusion: Extant data suggest that antidepressant treatment improves workplace outcomes in MDD. The capability of antidepressants in improving measures of workplace functioning should be considered in cost-benefit analyses to better inform cost-modelling studies pertaining to antidepressant therapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER SCIENCE BV | - |
dc.subject | LEVOMILNACIPRAN SUSTAINED-RELEASE | - |
dc.subject | DOUBLE-BLIND | - |
dc.subject | WORK PRODUCTIVITY | - |
dc.subject | COGNITIVE FUNCTION | - |
dc.subject | CONTROLLED-TRIAL | - |
dc.subject | GLOBAL BURDEN | - |
dc.subject | PHASE-III | - |
dc.subject | 40 MG | - |
dc.subject | PLACEBO | - |
dc.subject | VORTIOXETINE | - |
dc.title | Efficacy of antidepressants on measures of workplace functioning in major depressive disorder: A systematic review | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Jae-Hon | - |
dc.identifier.doi | 10.1016/j.jad.2017.11.003 | - |
dc.identifier.scopusid | 2-s2.0-85037662377 | - |
dc.identifier.wosid | 000424323600055 | - |
dc.identifier.bibliographicCitation | JOURNAL OF AFFECTIVE DISORDERS, v.227, pp.406 - 415 | - |
dc.relation.isPartOf | JOURNAL OF AFFECTIVE DISORDERS | - |
dc.citation.title | JOURNAL OF AFFECTIVE DISORDERS | - |
dc.citation.volume | 227 | - |
dc.citation.startPage | 406 | - |
dc.citation.endPage | 415 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | ssci | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalResearchArea | Psychiatry | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.relation.journalWebOfScienceCategory | Psychiatry | - |
dc.subject.keywordPlus | LEVOMILNACIPRAN SUSTAINED-RELEASE | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordPlus | WORK PRODUCTIVITY | - |
dc.subject.keywordPlus | COGNITIVE FUNCTION | - |
dc.subject.keywordPlus | CONTROLLED-TRIAL | - |
dc.subject.keywordPlus | GLOBAL BURDEN | - |
dc.subject.keywordPlus | PHASE-III | - |
dc.subject.keywordPlus | 40 MG | - |
dc.subject.keywordPlus | PLACEBO | - |
dc.subject.keywordPlus | VORTIOXETINE | - |
dc.subject.keywordAuthor | Depression | - |
dc.subject.keywordAuthor | Work | - |
dc.subject.keywordAuthor | Functioning | - |
dc.subject.keywordAuthor | Antidepressant | - |
dc.subject.keywordAuthor | Quality of life | - |
dc.subject.keywordAuthor | Functional outcomes | - |
dc.subject.keywordAuthor | Disability | - |
dc.subject.keywordAuthor | Cost modelling | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.